Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | SLC6A5 | Q9Y345 | 7/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6103458 | 0.92 | SLC6A9 (0.84) | SLC6A9KCNH2CYP2D6CYP3A4SLC6A5 | |
| SCHEMBL6103378 | 0.90 | SLC6A9 (0.84) | SLC6A9KCNH2CYP2D6CYP3A4SLC6A5 | |
| SCHEMBL6103428 | 0.89 | SLC6A9 (0.85) | SLC6A9KCNH2CYP2D6CYP3A4SLC6A5 | |
| SCHEMBL6103742 | 0.89 | SLC6A9 (0.84) | SLC6A9KCNH2CYP2D6CYP3A4SLC6A5 | |
| SCHEMBL15967232 | 0.88 | SLC6A9 (0.60) | SLC6A9KCNH2CYP2D6CYP3A4SLC6A5 | |
| SCHEMBL6103741 | 0.88 | SLC6A9 (0.78) | SLC6A9KCNH2CYP2D6CYP3A4SLC6A5 | |
| SCHEMBL6103641 | 0.88 | SLC6A9 (0.83) | SLC6A9KCNH2CYP2D6CYP3A4SLC6A5 | |
| SCHEMBL6103047 | 0.88 | SLC6A9 (0.85) | SLC6A9KCNH2CYP2D6CYP3A4SLC6A5 | |
| SCHEMBL6104480 | 0.88 | SLC6A9 (0.85) | SLC6A9KCNH2CYP2D6CYP3A4SLC6A5 | |
| SCHEMBL6104575 | 0.88 | SLC6A9 (1.00) | SLC6A9KCNH2CYP2D6CYP3A4SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060229455-A1 | Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors | PFIZER INC. | 2006-10-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229455-A1 | Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors | SLC1A2, SLC1A1, GLRA1 | SLC6A9 11/4885KCNH2 733/4885CYP2D6 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.